Calendar updated to include several drug approvals inadvertently omitted.

BOSTON (

TheStreet

) -- Here's an updated list of biotech and pharmaceutical companies with pending FDA drug approval decisions for the rest of 2012.

The calendar on the following pages captures the most important U.S. regulatory events -- FDA drug approvals and advisory panels -- expected between May and December 2012. As every savvy biotech investor and trader knows, the volatility in biotech and drug stocks ramps significantly as U.S. regulators weigh whether to approve or reject new drugs.

Biotech and drug stocks below are listed in chronological order based on the closest regulatory catalyst. The calendar was compiled with some assistance from

BioMedTracker.com

, a very useful database of experimental drug and drug-development catalysts compiled by Sagient Research.

Alexza Pharmaceuticals

(ALXA)

Drug/indication:

Adasuve for agitation related to schizophrenia

Approval decision date:

May 4

A drug inhaled into the lungs, a split FDA advisory panel vote and lingering safety concerns make Adasuve's approval odds a tough call.

Regeneron Pharmaceuticals

(REGN) - Get Report

Drug/indication:

Arcalyst for prevention of gout flares

FDA advisory panel date:

May 8

Approval decision date:

July 30

This will be the second approved indication for Arcalyst, which is currently marketed as a treatment for cryopyrin-associated periodic syndromes (CAPS).

Pfizer

(PFE) - Get Report

Drug/indication:

Tofacitinib for rheumatoid arthritis

FDA advisory panel date:

May 9

Approval decision date:

August (exact date not specified)

Tofacitinib would be the first pill approved for the treatment of rheumatoid arthritis, competing with established injectable drugs like Abbbot's Humira.

Arena Pharmaceuticals

(ARNA) - Get Report

Drug/indication:

Lorcaserin for obesity

FDA advisory panel date:

May 10

Approval decision date:

June 27

This is the second review cycle for lorcaserin.

Gilead Sciences

(GILD) - Get Report

Drug/indication:

Quad for HIV

FDA advisory panel date:

May 11

Approval decision date:

Aug. 27

Quad combines four Gilead drugs into a single, once-daily pill for HIV. The new (and still experimental) components in the Quad are the integrase inhibitor elvitegravir and cobicistat, which is used to boost blood levels of elvitegravir.

Talon Therapeutics

( TLON)

Drug/indication:

Marqibo for advanced acute lymphoblastic leukemia

Approval decision date:

May 13

In March, an FDA advisory panel voted to recommend approval of Marqibo.

Merck

(MRK) - Get Report

and

Ariad Pharmaceuticals

(ARIA)

Drug/indication:

Taltorvic for sarcoma

Approval decision date:

June 5

In March, an FDA advisory panel recommended against approval of Taltorvic.

Roche

(RHHBY)

Drug/indication:

Pertuzumab for HER2-positive metastatic breast cancer

Approval decision date:

June 8

Onyx Pharmaceuticals

(ONXX)

Drug/indication:

Carfilzomib for relapsed/refractory multiple myeloma

FDA advisory panel date:

June 20

Approval decision date:

July 27

Bristol-Myers Squibb

(BMY) - Get Report

and

Pfizer

Drug/indication:

Eliquis for stroke prevention in patients with atrial fibrillation

Approval decision date:

June 28

FDA delayed the Eliquis approval decision by three months.

Celgene

(CELG) - Get Report

Drug/indication:

Revlimid in first-line multiple myeloma

European approval decision date:

Second or third quarter

This calendar is focused on U.S. regulatory decisions, but Celgene's efforts to get Revlimid approved as a first-line treatment for multiple myeloma in Europe is crucial for the company's growth and stock price.

Vivus

(VVUS) - Get Report

Drug/indication:

Qnexa for obesity

Approval decision date:

July 17

A February FDA advisory panel voted 20-2 to support Qnexa's approval. FDA's decision was delayed by three months to allow the company and regulators to finalize a risk-management plan.

Amarin

(AMRN) - Get Report

Drug/indication:

AMR101 for treatment of patients with very high triglycerides

Approval decision date:

July 26

Horizon Pharma

(HZNP) - Get Report

Drug/indication:

Lodotra for rheumatoid arthritis

Approval decision date:

July 26

Progenics

(PGNX) - Get Report

and

Salix Pharmaceuticals

(SLXP)

Drug/indication:

Relistor SC for opioid-induced constipation

Approval decision date:

July 27

Regeneron Pharmaceuticals

and

Sanofi

(SNY) - Get Report

Drug/indication:

Zaltrap for colon cancer

Approval decision date:

Aug. 4

Zaltrap has posted mixed results in phase III clinical trials.

Ironwood Pharmaceuticals

(IRWD) - Get Report

Drug/indication:

Linaclotide for chronic idiopathic constipation and irritable bowel syndrome

Approval decision date:

Sept. 8

Navidea Biopharmaceuticals

(NAVB) - Get Report

Drug/indication:

Lymphoseek, a radioactive tracing agent for lymph node mapping

Approval decision date:

Sept. 10

Regeneron Pharmaceuticals

Drug/indication:

Eylea for retinal vein occlusion

Approval decision date:

Sept. 21

This is an expanded approval for Eylea, already approved for macular degeneration.

NPS Pharmaceuticals

(NPSP)

Drug/indication:

Gattex for short bowel syndrome

Approval decision date:

Sept. 28

Sanofi

and

Isis Pharmaceuticals

(ISIS)

Drug/indication:

Kynamro for hypercholesterolemia

Approval decision date:

Sept. 28

Raptor Pharmaceutical

(RPTP)

Drug/indication:

RP103 for cystinosis

Approval decision date:

Oct. 1

Celgene

Drug/indication:

Abraxane for non-small cell lung cancer

Approval decision date:

Oct. 12

Abraxane is already approved for the treatment of breast cancer.

Santarus

(SNTS)

Drug/indication:

Uceris for ulcerative colitis

Approval decision date:

Oct. 16

Impax Labs

(IPAX)

Drug/indication:

IPX066 for Parkinson's disease

Approval decision date:

Oct. 19

Dynavax

(DVAX) - Get Report

Drug/indication:

Heplisav for hepatitis B prevention

Approval decision date:

Oct. 26

United Therapeutics

(UTHR) - Get Report

Drug/indication:

Oral Remodulin for pulmonary arterial hypertension

Approval decision date:

Oct. 26

Cornerstone Therapeutics

(CRTX) - Get Report

Drug/indication:

Lixivaptan for hyponatremia

Approval decision date:

Oct. 29

Celgene

Drug/indication:

pomalidomide for refractory/relapsed multiple myeloma

Approval decision date:

Fourth quarter

Celgene announced submission of the pomalidomide filing during the second quarter.

Biogen Idec

(BIIB) - Get Report

Drug/indication:

BG-12 for multiple sclerosis

Approval decision date:

Dec. 28

BG-12 would be Biogen's first pill for multiple sclerosis.

--Written by Adam Feuerstein in Boston.

>To contact the writer of this article, click here:

Adam Feuerstein

.

>To follow the writer on Twitter, go to

http://twitter.com/adamfeuerstein

.

>To submit a news tip, send an email to:

tips@thestreet.com

.

Follow

TheStreet

on

Twitter

and become a fan on

Facebook.

Adam Feuerstein writes regularly for TheStreet. In keeping with company editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback;

click here

to send him an email.